
Nicholas Manolios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5518615/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Molecular Immunology, 1997, 34, 577-582.	2.2	242
2	Transmembrane helical interactions and the assembly of the T cell receptor complex. Science, 1990, 249, 274-277.	12.6	223
3	Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor EMBO Journal, 1991, 10, 1643-1651.	7.8	156
4	T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nature Medicine, 1997, 3, 84-88.	30.7	113
5	Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 2015, 38, 37-39.	2.4	112
6	Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor EMBO Journal, 1992, 11, 3245-3254.	7.8	96
7	Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care and Research, 2018, 70, 39-52.	3.4	95
8	The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. European Journal of Rheumatology, 2017, 4, 210-218.	0.6	87
9	New onset sarcoidâ€like granulomatosis developing during antiâ€TNF therapy: an underâ€recognised complication. Internal Medicine Journal, 2012, 42, 89-94.	0.8	83
10	The T cell antigen receptor α and β chains interact via distinct regions with CD3 chains. European Journal of Immunology, 1994, 24, 84-92.	2.9	79
11	Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. British Journal of Rheumatology, 1999, 38, 645-651.	2.3	71
12	Familial risk estimation in systemic sclerosis. Australian and New Zealand Journal of Medicine, 1999, 29, 36-41.	0.5	61
13	The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis. Seminars in Arthritis and Rheumatism, 2009, 39, 182-196.	3.4	54
14	Lupus Means Sacrifices: Perspectives of Adolescents and Young Adults With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 828-837.	3.4	53
15	Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. EMBO Journal, 1991, 10, 1643-51.	7.8	53
16	Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clinical Immunology, 2014, 151, 43-54.	3.2	50
17	Family and twin studies in systemic lupus erythematosus. Disease Markers, 1997, 13, 93-8.	1.3	48
18	Advanced refractory polymyositis responding to infliximab. British Journal of Rheumatology, 2005, 44, 562-563.	2.3	42

#	Article	IF	CITATIONS
19	Secondary screening for osteoporosis in patients admitted with minimal-trauma fracture to a major teaching hospital. Internal Medicine Journal, 2003, 33, 505-510.	0.8	37
20	Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. European Journal of Immunology, 1991, 21, 1703-1709.	2.9	36
21	Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 879-888.	4.1	35
22	Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides, 2011, 32, 1567-1574.	2.4	35
23	Gene therapy in diabetes. Self/nonself, 2010, 1, 165-175.	2.0	34
24	T Cell Antigen Receptor Peptide-Lipid Membrane Interactions Using Surface Plasmon Resonance. Journal of Biological Chemistry, 2004, 279, 54002-54007.	3.4	33
25	T-Cell Antigen Receptor Peptides Inhibit Signal Transduction within the Membrane Bilayer. Clinical Immunology, 2002, 105, 199-207.	3.2	32
26	X-Chromosome Inactivation in Monozygotic Twins with Systemic Lupus Erythematosus. Autoimmunity, 1997, 26, 85-93.	2.6	31
27	The motherhood choices decision aid for women with rheumatoid arthritis increases knowledge and reduces decisional conflict: a randomized controlled trial. BMC Musculoskeletal Disorders, 2015, 16, 260.	1.9	30
28	T cell antigen receptor (TCR) transmembrane peptides colocalize with TCR, not lipid rafts, in surface membranes. Cellular Immunology, 2002, 215, 12-19.	3.0	29
29	Enhanced interferon-gamma (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice. Clinical and Experimental Immunology, 1989, 76, 301-6.	2.6	29
30	Methotrexate: longâ€ŧerm safety and efficacy in an Australian consultant rheumatology practice. Internal Medicine Journal, 2009, 39, 228-236.	0.8	27
31	Navigating Motherhood Choices in the context of Rheumatoid Arthritis: Women's Stories. Musculoskeletal Care, 2013, 11, 73-82.	1.4	26
32	Investigation of the –1377 polymorphism on the apo-1/fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology, 2000, 32, 126-130.	0.6	25
33	Kinetic and conformational properties of a novel Tâ€cell antigen receptor transmembrane peptide in model membranes. Journal of Peptide Science, 2008, 14, 714-724.	1.4	25
34	High endothelial venule morphology and function are inducible in germ-free mice: A possible role for interferon-Î ³ . Cellular Immunology, 1988, 117, 136-151.	3.0	24
35	Magnetic resonance imaging in Löfgren's syndrome: demonstration of periarthritis. Clinical Rheumatology, 2007, 26, 572-575.	2.2	21
36	A Fas promoter polymorphism at position â^'670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes. Rheumatology, 1999, 38, 883-886.	1.9	20

#	Article	IF	CITATIONS
37	Evaluation of the Apo-1/Fas promoter Mva I polymorphism in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 14-18.	3.0	20
38	Clopidogrel-associated acute arthritis. Internal Medicine Journal, 2003, 33, 618-619.	0.8	20
39	Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function. Immunology, 2003, 108, 458-464.	4.4	19
40	Proteomics in Rheumatology: A New Direction for Old Diseases. Seminars in Arthritis and Rheumatism, 2005, 35, 67-76.	3.4	19
41	Discrepancy in CD3-Transmembrane Peptide Activity between In Vitro and In Vivo T-Cell Inhibition. Scandinavian Journal of Immunology, 2006, 64, 388-391.	2.7	19
42	Systemic scleroderma: a spatiotemporal clustering. Internal Medicine Journal, 2005, 35, 228-233.	0.8	18
43	Hydrophobic Transmembrane-Peptide Lipid Conjugations Enhance Membrane Binding and Functional Activity in T-Cells. Bioconjugate Chemistry, 2005, 16, 1556-1563.	3.6	18
44	Clinical images: Calcifying pseudoneoplasm of the neuraxis. Arthritis and Rheumatism, 2010, 62, 704-704.	6.7	17
45	Immunogenetic analysis of 5 families with multicase occurrence of scleroderma and/or related variants. Journal of Rheumatology, 1995, 22, 85-92.	2.0	17
46	Anti-la monoclonal antibody (10-2.16) inhibits lymphocyte-high endothelial venule (HEV) interaction. Cellular Immunology, 1988, 117, 152-164.	3.0	16
47	Lymphocyte migration in health and inflammatory rheumatic disease. Seminars in Arthritis and Rheumatism, 1991, 20, 339-352.	3.4	16
48	Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. Annals of the Rheumatic Diseases, 2006, 65, 1247-1248.	0.9	16
49	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 2019, 9, 14834.	3.3	16
50	The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. European Journal of Rheumatology, 2020, 7, S91-S93.	0.6	16
51	LETTERS TO THE EDITOR. Australasian Journal of Dermatology, 2002, 43, 226-227.	0.7	15
52	Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis. International Journal of Rheumatic Diseases, 2018, 21, 1915-1923.	1.9	15
53	A family study of allergy: Segregation with HLA but not with T-cell receptor genes. Journal of Allergy and Clinical Immunology, 1996, 97, 712-713.	2.9	14
54	T-Cell Antigen Receptor-alpha Chain Transmembrane Peptides: Correlation between Structure and Function. International Journal of Peptide Research and Therapeutics, 2006, 12, 261-267.	1.9	14

#	Article	IF	CITATIONS
55	Immunoreceptor Transmembrane Peptides and Their Effect on Natural Killer (NK) Cell Cytotoxicity. Protein and Peptide Letters, 2006, 13, 1017-1024.	0.9	14
56	Reconstructive Hand Surgery for Scleroderma Joint Contractures. Journal of Hand Surgery, 2007, 32, 1107-1112.	1.6	14
57	P2X ₇ gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. Tissue Antigens, 2008, 72, 487-490.	1.0	14
58	Hierarchy of T cell antigen receptor assembly. Immunology and Cell Biology, 1995, 73, 544-548.	2.3	13
59	Endocannabinoids in arthritis: current views and perspective. International Journal of Rheumatic Diseases, 2017, 20, 789-797.	1.9	13
60	Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma. Clinical Rheumatology, 2007, 26, 1136-1141.	2.2	11
61	Effectiveness of moving on: an Australian designed generic self-management program for people with a chronic illness. BMC Health Services Research, 2013, 13, 90.	2.2	11
62	Therapeutic Application of Transmembrane T and Natural Killer Cell Receptor Peptides. Advances in Experimental Medicine and Biology, 2008, 640, 208-219.	1.6	11
63	Structural mutations in the constant region of the T-cell antigen receptor (TCR)beta chain and their effect on TCR alpha and beta chain interaction. Immunology, 1996, 88, 524-30.	4.4	11
64	Peptide delivery systems. International Journal of Peptide Research and Therapeutics, 2001, 8, 289-294.	0.1	10
65	CCR5 Genotyping in an Australian and New Zealand Type 1 Diabetes Cohort. Autoimmunity, 2002, 35, 457-461.	2.6	10
66	Relationship of tumour necrosis factor alpha gene polymorphisms and neuropsychiatric lupus. Lupus, 2002, 11, 114-118.	1.6	10
67	Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab. Clinical Rheumatology, 2009, 28, 1349-1350.	2.2	10
68	T-Cell Antigen Receptor Assembly and Cell Surface Expression Is Not Affected by Treatment with T-Cell Antigen Receptor-Alpha Chain Transmembrane Peptide. Protein and Peptide Letters, 2007, 14, 299-303.	0.9	9
69	Cyclization enhances function of linear anti-arthritic peptides. Clinical Immunology, 2014, 150, 121-133.	3.2	9
70	Evaluating disease activity in patients with ankylosing spondylitis and rheumatoid arthritis using 99mtc-glucosamine. European Journal of Rheumatology, 2016, 3, 65-72.	0.6	9
71	Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. Internal Medicine Journal, 2008, 38, 080311021334281-???.	0.8	8
72	Evidenceâ€based recommendations for the diagnosis of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. Medical Journal of Australia, 2008, 188, 235-237.	1.7	8

#	Article	IF	CITATIONS
73	Biopsy Diagnosis of Early Myositis Ossificans Without Radiologic Evidence of Calcification. Journal of Clinical Rheumatology, 2010, 16, 385-387.	0.9	8
74	T-cell antigen receptor (TCR) transmembrane peptides. Cell Adhesion and Migration, 2010, 4, 273-283.	2.7	8
75	Acute arthritis: predictive factors and current practice in the approach to diagnosis and management across two hospitals in Sydney. Internal Medicine Journal, 2018, 48, 1087-1095.	0.8	8
76	Biophysical studies of a transmembrane peptide derived from the T cell antigen receptor. International Journal of Peptide Research and Therapeutics, 2001, 8, 227-233.	0.1	7
77	Novel cationic lipophilic peptides for oligodeoxynucleotide delivery. Bioorganic and Medicinal Chemistry, 2007, 15, 4091-4097.	3.0	7
78	The mode of anti-arthritic peptide delivery impacts on the severity and outcome of adjuvant induced arthritis. APLAR Journal of Rheumatology, 2007, 10, 198-203.	0.2	7
79	The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease. Nuclear Medicine Communications, 2014, 35, 655-665.	1.1	7
80	The utility of dual energy computed tomography in the management of axial gout: case reports and literature review. BMC Rheumatology, 2020, 4, 22.	1.6	7
81	CURRENT CONCEPTS IN THE ETIOPATHOGENESIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Australian and New Zealand Journal of Medicine, 1986, 16, 729-743.	0.5	6
82	Biophysical studies of a transmembrane peptide derived from the T cell antigen receptor. International Journal of Peptide Research and Therapeutics, 2001, 8, 227-233.	0.1	6
83	99mTc-technetium labeling of antiarthritic peptides to evaluate homing and biodistribution at inflamed joints. Nuclear Medicine and Biology, 2011, 38, 751-756.	0.6	6
84	NMR study of the structure and selfâ€association of core peptide in aqueous solution and DPC micelles. Biopolymers, 2011, 96, 177-180.	2.4	6
85	Alanine Scan of an Immunosuppressive Peptide (CP): Analysis of Structure–Function Relationships. Chemical Biology and Drug Design, 2013, 81, 167-174.	3.2	6
86	A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment. Journal of Health Psychology, 2013, 18, 1353-1359.	2.3	6
87	Leptomeningitis in rheumatoid arthritis. European Journal of Rheumatology, 2021, 8, 48-50.	0.6	6
88	The T cell antigen receptor beta chain interacts with the extracellular domain of CD3â€Î³. Immunology and Cell Biology, 1995, 73, 532-536.	2.3	5
89	The Interchain Disulfide Linkage of T-Cell Antigen Receptor-α and -β Chains Is a Prerequisite for T-Cell Activation. Cellular Immunology, 1998, 190, 101-111.	3.0	5
90	Histiocytosis and bone: experience from one major Sydney teaching hospital. Internal Medicine Journal, 2005, 35, 622-625.	0.8	5

#	Article	IF	CITATIONS
91	No more excuses: fracture liaison services work and are costâ€effective. Medical Journal of Australia, 2012, 196, 384-384.	1.7	5
92	Hypothesis: TCR signal transduction—A novel tri-modular signaling system. Molecular Immunology, 2008, 45, 876-880.	2.2	4
93	Antitopoisomerase antibody positivity predates nailfold capillaroscopy abnormalities in scleroderma. Postulated classification of â€~prescleroderma'. Internal Medicine Journal, 2011, 41, 197-199.	0.8	4
94	Checkpoint inhibitors and arthritis. Annals of the Rheumatic Diseases, 2019, 78, e58-e58.	0.9	4
95	The diagnostic accuracy of temporal artery ultrasound and temporal artery biopsy in giant cell arteritis: A single center Australian experience over 10Âyears. International Journal of Rheumatic Diseases, 2022, 25, 447-453.	1.9	4
96	Lymphocyte Migration Patterns in Autoimmune MRL-lpr/lpr Mice: Relationship to Age, Disease Manifestations and Lymphocyte Homing Receptor Expression. Autoimmunity, 1989, 3, 5-15.	2.6	3
97	Renal disease and rheumatic manifestations. Current Opinion in Rheumatology, 1994, 6, 82-84.	4.3	3
98	Conformation of the Tâ€Cell Antigen Receptorâ€Î² Chain Câ€Domain Contributes to Vβ 3 Epitope Recognition by Monoclonal Antibody KJ25. Scandinavian Journal of Immunology, 1996, 43, 140-145.	2.7	3
99	Familial scleroderma: nature, nurture or both?. Internal Medicine Journal, 2008, 38, 235-242.	0.8	3
100	Novel T-cell inhibiting peptides delay the onset of Type 1 diabetes in non-obese diabetic mice. Diabetes and Metabolism, 2014, 40, 229-234.	2.9	3
101	Musculoskeletal immuneâ€related adverse events with the use of checkpoint inhibitors in malignancy. Internal Medicine Journal, 2022, 52, 818-827.	0.8	3
102	<scp>Epstein–Barr</scp> virusâ€related lymphoma in rheumatoid arthritis: implications for longâ€term usage of immunosuppressive drugs and review of the literature. Internal Medicine Journal, 2022, 52, 1717-1723.	0.8	3
103	An enquiry into the crippling gout affecting Pacific Islander and MÄori men in Western Sydney. International Journal of Rheumatic Diseases, 2021, 24, 1394-1401.	1.9	3
104	Aberrant Lymphocyte Migration Patterns in Systemic Lupus Erythematosus (MRL/l, MRL/n) Mice are Independent of the Micro-Environment. Autoimmunity, 1990, 7, 139-148.	2.6	2
105	Chemotherapeutic induced fascial oedema. Annals of the Rheumatic Diseases, 2005, 64, 162-163.	0.9	2
106	Failure of anti-TNF therapy to reactivate previously septic prosthetic joints. BMJ Case Reports, 2013, 2013, bcr2013009827-bcr2013009827.	0.5	2
107	99mTc-labelled glucosamine in the assessment of systemic sclerosis inflammatory lung disease: a novel inexpensive investigative tool with predictive value Annals of Nuclear Medicine, 2021, 35, 1157-1166.	2.2	2
108	Correspondence on â€~Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?'. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219694.	0.9	2

#	Article	IF	CITATIONS
109	The disproportionately large contribution of the MÄori and Pacific Islander community to the healthcare burden of gout in Western Sydney. Internal Medicine Journal, 2023, 53, 1450-1457.	0.8	2
110	Pseudo-avascular necrosis of the hips in a sporadic case of osteopetrosis. Clinical Rheumatology, 1987, 6, 408-411.	2.2	1
111	Arachidonic acid metabolites in normal and autoimmune mice do not influence lymphocyteâ€high endothelial venule interactions. Immunology and Cell Biology, 1991, 69, 39-46.	2.3	1
112	Role of Tâ€cell antigen receptors in rheumatic disease. Australian and New Zealand Journal of Medicine, 1993, 23, 205-212.	0.5	1
113	Charles Bonnet Syndrome in Giant Cell Arteritis. Journal of Clinical Rheumatology, 1998, 4, 144-146.	0.9	1
114	Peptide delivery systems. International Journal of Peptide Research and Therapeutics, 2001, 8, 289-294.	0.1	1
115	Peptide-based therapies for arthritis. Future Rheumatology, 2007, 2, 287-296.	0.2	1
116	Pseudohypercalcaemia in mixed cryoglobulinaemia (IgMκ/polyclonal IgG): a rare complication of Sjögren's syndrome. Clinical Rheumatology, 2010, 29, 439-441.	2.2	1
117	Cauda Equina Syndrome in Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2013, 19, 163.	0.9	1
118	Assessing Cognitive Function in Rheumatoid Arthritis: Comment on the Article by Shin et al. Arthritis Care and Research, 2013, 65, 1390-1390.	3.4	1
119	Acute gross painless transudative ascites in a patient with lupus. BMJ Case Reports, 2014, 2014, bcr2013201503-bcr2013201503.	0.5	1
120	Coturnism. Internal Medicine Journal, 2018, 48, 1009-1009.	0.8	1
121	Arthritis in the hands of saints. Rheumatology International, 2021, 41, 1705-1706.	3.0	1
122	Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints. Current Drug Delivery, 2011, 8, 600-606.	1.6	1
123	Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines. Iranian Journal of Basic Medical Sciences, 2014, 17, 772-8.	1.0	1
124	The use of biologies in the treatment of rheumatoid arthritis (RA). Australian and New Zealand Journal of Medicine, 1997, 27, 607-607.	0.5	0
125	Photoactive benzophenone labelled peptide. APLAR Journal of Rheumatology, 2004, 7, 11-12.	0.2	0
126	Hypercarotenaemia. Internal Medicine Journal, 2006, 36, 534-534.	0.8	0

8

#	Article	IF	CITATIONS
127	Resolution of skin fibrosis and joint contractures in aggressive diffuse systemic sclerosis using autologous stem cell transplantation. APLAR Journal of Rheumatology, 2006, 9, 298-301.	0.2	0
128	Evidence-based recommendations for the monitoring and treatment of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. International Journal of Rheumatic Diseases, 2008, 11, 45-49.	1.9	0
129	AUTOIMMUNITY AND THE MUSCULOSKELETAL SYSTEM. , 2010, , 123-135.		0
130	AB0074â€INTERRELATIONSHIP BETWEEN NICOTINIC ACETYLCHOLINE RECEPTOR AND CYTOKINE PRODUCTIO NOTED FOLLOWING T-CELL ANTIGEN RECOGNITION AND ACTIVATION. , 2019, , .	N	0
131	The ha(r)shâ€drug interactions in rheumatology. International Journal of Rheumatic Diseases, 2020, 23, 1258-1260.	1.9	0